Magentiq-Eye Ltd. received U.S. FDA 510(k) clearance for its Magentiq-Colo, an artificial intelligence (AI) gastrointestinal software system that helps detect lesions in real time during colonoscopy procedures. With the rate of colorectal cancer expected to increase steadily through the decade, the company hopes that Magentiq-Colo will offer the gastroenterology community and its patients a significant increase in the adenoma detection rate.
Research at Beigene Co. Ltd. has led to the identification of new proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase binding moiety covalently linked to a Bruton tyrosine kinase (BTK) targeting moiety via linker. They are reported to be useful for the treatment of cancer.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have jointly patented tricyclic compounds acting as mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors. As such, they are reported to be useful for the treatment of cancer and autoimmune diseases.
JS Innomed Holdings Ltd. and JS Innopharm Ltd. have developed new tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer, LEOPARD syndrome and Noonan syndrome.
Fuzionaire Diagnostics Inc. has changed its name to Fuzionaire Theranostics Inc. to better reflect the company’s pipeline of paired fluorine-18 PET diagnostics and radioligand therapies to find and treat cancer.
Researchers from Delta-Fly Pharma Inc. presented preclinical data for DFP-14927, a polyethylene glycol (PEG)-conjugate of a deoxycytidine analogue, being developed as a potential anticancer agent.
Researchers from Zhejiang University of Technology presented the discovery of novel small compound candidates, designed with the aim of overcoming P-glycoprotein (P-gp)-mediated multidrug resistance (MDR).
Critically shortened telomeres are a key limiting factor in successful CAR T-cell immunotherapy, with cells from older patients tending to have shorter telomeres with reduced dividing capacity. As such, these cells are unable to fully eliminate malignancies and provide durable and persistent protection against cancer.
The notion of taking aim at the galectin pathway across varied therapeutic areas has gained major traction in recent years, with a handful of companies drawing Wall Street’s interest as efforts plow forth in conditions as varied as cancer, liver fibrosis and Alzheimer’s disease.
Citius Pharmaceuticals Inc.’s retooled version of withdrawn cancer drug Ontak (denileukin diftitox) is not quite ready for prime time, according to the U.S. FDA, which issued a complete response letter (CRL) for the interleukin-2-diphtheria toxin fusion protein known as Lymphir. The agency is asking for Citius to incorporate enhanced product testing and additional controls but did not raise any concerns regarding safety and efficacy, the company said.
RSS
